BioSpace News Archive

Nucleus Biologics, The Cell Performance Company™, an industry-leading provider of small lot custom cell culture media, celebrated the opening of its newest building on their San Diego campus and the unveiling of additional state-of-the-art cleanrooms and infrastructure at a ribbon cutting ceremony on September 22.

Epiphany Technology Acquisition Corp. (the “Company”) announced today that the company’s Board of Directors (the “Board”) has approved an increase in the size of the Board from seven (7) directors to eleven (11) directors and elected Ross Haghighat, Stephen Sherwin, Ronald Eastman and Louis Lange as members of the Board.

The global Electrocardiograph market size was estimated at USD 9.2 billion in 2021 and is expected to surpass around USD 21.7 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 10% during the forecast period 2022 to 2030.

Concord Medical Services Holdings Limited (“Concord Medical” or the “Company”) (NYSE: CCM) today announced its unaudited consolidated financial results for the six months ended June 30, 2022[1].

Caryl Boies professor of cancer research at Cold Spring Harbor Laboratory (CSHL), and his team have found a drug candidate that can prevent lethal lung inflammation in mice by inhibiting a protein called PTP1B.

Palisade Bio, Inc. announced that it had made equity grants to two new employees under its 2021 Inducement Plan.

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today reported financial results for the fiscal year ended June 30, 2022.

Biotech and medical AI innovator Surge announced a $2.6 million round co-led by HCVC, a global early-stage fund dedicated to high-potential technology startups, and Boutique Venture Partners, a leading fund based in the Silicon Valley.

PDS Biotechnology Corporation announced PDS Biotech granted nonstatutory stock options to Amber King, PDS Biotech’s Clinical Trial Assistant, to purchase 5,000 shares of PDS Biotech common stock.